CARISMA Therapeutics Q3 EPS $(0.53) Beats $(0.57) Estimate, Sales $3.83M Beat $1.20M Estimate
Portfolio Pulse from Benzinga Newsdesk
CARISMA Therapeutics (NASDAQ:CARM) reported Q3 losses of $(0.53) per share, beating the analyst consensus estimate of $(0.57) by 7.02%. This is a 93.67% increase over losses from the same period last year. The company also reported quarterly sales of $3.83 million, beating the analyst consensus estimate of $1.20 million by 218.92%. This is a 48.45% increase over sales from the same period last year.
November 09, 2023 | 12:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CARISMA Therapeutics reported better than expected Q3 results with losses per share and sales beating analyst estimates. This could potentially lead to a positive market reaction.
CARISMA Therapeutics reported better than expected Q3 results, with both losses per share and sales beating analyst estimates. This positive financial performance could potentially lead to a positive market reaction, as it indicates the company is performing better than expected.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100